Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells

International Journal of Pharmaceutics

Volumn 364, Issue 2, 2008, Pages 258-264

  Schiffelers, Raymond M ^a   Storm, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Angiogenesis; Cancer; Inflammation; Liposomes; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ANGIOGENESIS; CELL TYPE; ENDOTHELIUM CELL; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; INNATE IMMUNITY; MESENCHYME CELL; METASTASIS; NANOMEDICINE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; REVIEW; TARGET CELL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS;

EID: 55849117701     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.08.005     Document Type: Review

References (73)

1. Abraham S.A., Waterhouse D.N., Mayer L.D., Cullis P.R., Madden T.D., and Bally M.B. The liposomal formulation of doxorubicin. Methods Enzymol. 391 (2005) 71-97
2. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
3. Armulik A., Abramsson A., and Betsholtz C. Endothelial/pericyte interaction. Circ. Res. 97 (2005) 512-523
4. Asai T., Miyazawa S., Maeda N., Hatanaka K., Katanasaka Y., Shimizu K., Shuto S., and Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Cancer Sci. 99 (2008) 1029-1033
5. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., Taki T., Shuto S., Matsuda A., and Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett. 520 (2002) 167-170
6. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
7. Banciu M., Schiffelers R.M., Fens M.H., Metselaar J.M., and Storm G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J. Control. Release 113 (2006) 1-8
8. Banciu M., Metselaar J.M., Schiffelers R.M., and Storm G. Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. Neoplasia 10 (2008) 108-117
9. Barbolina M.V., and Stack M.S. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 19 (2008) 24-33
10. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., Torchilin V.P., and Munn L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62 (2002) 6831-6836
11. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
12. Chiu G.N., Bally M.B., and Mayer L.D. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim. Biophys. Acta 1613 (2003) 115-121
13. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
14. De Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (2006) 24-37
15. Dubey P.K., Mishra V., Jain S., Mahor S., and Vyas S.P. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug Target 12 (2004) 257-264
16. Eichhorn M.E., Strieth S., Krasnici S., Sauer B., Teifel M., Michaelis U., Naujoks K., and Dellian M. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 7 (2004) 133-141
17. Filer A., Pitzalis C., and Buckley C.D. Targeting the stromal microenvironment in chronic inflammation. Curr. Opin. Pharmacol. 6 (2006) 393-400
18. Flavell S.J., Hou T.Z., Lax S., Filer A.D., Salmon M., and Buckley C.D. Fibroblasts as novel therapeutic targets in chronic inflammation. Br. J. Pharmacol. 153 (2008) S241-S246
19. Gadea B.B., and Joyce J.A. Tumour-host interactions: implications for developing anti-cancer therapies. Expert Rev. Mol. Med. 8 (2006) 1-32
20. Gardner S.N., and Fernandes M. Cytostatic anticancer drug development. J. Exp. Ther. Oncol. 4 (2004) 9-18
21. Genis L., Galvez B.G., Gonzalo P., and Arroyo A.G. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev. 25 (2006) 77-86
22. Gerhardt H., and Semb H. Pericytes: gatekeepers in tumour cell metastasis?. J. Mol. Med. 86 (2008) 135-144
23. Gosk S., Moos T., Gottstein C., and Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim. Biophys. Acta 1778 (2008) 854-863
24. Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005) 849-860
25. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., Yasuda J., Obata K., Kikuchi H., Ishida T., Kiwada H., and Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 342 (2007) 194-200
26. Itoh Y., and Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J. Cell. Physiol. 206 (2006) 1-8
27. Janssen A.P., Schiffelers R.M., Ten Hagen T.L., Koning G.A., Schraa A.J., Kok R.J., Storm G., and Molema G. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int. J. Pharm. 254 (2003) 55-58
28. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., and Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4 (2003) 393-403
29. Kalra A.V., and Campbell R.B. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm. Res. 23 (2006) 2809-2817
30. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 358 (2008) 2039-2049
31. Kim D.W., Andres M.L., Miller G.M., Cao J.D., Green L.M., Seynhaeve A.L., Ten Hagen T.L., and Gridley D.S. Immunohistological analysis of immune cell infiltration of a human colon tumor xenograft after treatment with Stealth liposome-encapsulated tumor necrosis factor-alpha and radiation. Int. J. Oncol. 21 (2002) 973-979
32. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., Taki T., Baba K., and Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 108 (2004) 301-306
33. Koning G.A., Fretz M.M., Woroniecka U., Storm G., and Krijger G.C. Targeting liposomes to tumor endothelial cells for neutron capture therapy. Appl. Radiat. Isot. 61 (2004) 963-967
34. Kunstfeld R., Wickenhauser G., Michaelis U., Teifel M., Umek W., Naujoks K., Wolff K., and Petzelbauer P. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J. Invest. Dermatol. 120 (2003) 476-482
35. Kuramoto Y., Kawakami S., Zhou S., Fukuda K., Yamashita F., and Hashida M. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. J. Control. Release 126 (2008) 274-280
36. Kuramoto Y., Kawakami S., Zhou S., Fukuda K., Yamashita F., and Hashida M. Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. J. Gene Med. 10 (2008) 392-399
37. Kuramoto Y., Nishikawa M., Hyoudou K., Yamashita F., and Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J. Control. Release 115 (2006) 226-233
38. Ludwig H., Strasser-Weippl K., Schreder M., and Zojer N. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann. Oncol. 18 (2007) ix64-70
39. Maeda N., Miyazawa S., Shimizu K., Asai T., Yonezawa S., Kitazawa S., Namba Y., Tsukada H., and Oku N. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol. Pharm. Bull. 29 (2006) 1936-1940
40. Maeda N., Takeuchi Y., Takada M., Namba Y., and Oku N. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate. Bioorg. Med. Chem. Lett. 14 (2004) 1015-1017
41. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., and Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release 100 (2004) 41-52
42. Martinez F.O., Sica A., Mantovani A., and Locati M. Macrophage activation and polarization. Front. Biosci. 13 (2008) 453-461
43. Mauel J. Activation and cytotoxic activity of macrophages: a short review. Recent Results Cancer Res. (1976) 31-40
44. Mclean J.W., Fox E.A., Baluk P., Bolton P.B., Haskell A., Pearlman R., Thurston G., Umemoto E.Y., and Mcdonald D.M. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am. J. Physiol. 273 (1997) H387-H404
45. Miselis N.R., Wu Z.J., Van Rooijen N., and Kane A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 7 (2008) 788-799
46. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., Van Der Schaft D.W., Storm G., Koning G.A., Griffioen A.W., and Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 19 (2005) 2008-2010
47. Nanda A., and St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 16 (2004) 44-49
48. Noonan D.M., De Lerma Barbaro A., Vannini N., Mortara L., and Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 27 (2008) 31-40
49. O'brien M.E. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 19 (2008) 1-7
50. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., Ogino K., Tanaka M., Ishikawa D., Tsukada H., Momose M., Nakayama J., and Taki T. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21 (2002) 2662-2669
51. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., and Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003) 7400-7409
52. Pattillo C.B., Sari-Sarraf F., Nallamothu R., Moore B.M., Wood G.C., and Kiani M.F. Targeting of the antivascular drug combretastatin to irradiated tumors results in tumor growth delay. Pharm. Res. 22 (2005) 1117-1120
53. Perez-Lopez M.E., Curiel T., Gomez J.G., and Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 18 (2007) 611-617
54. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., Dames S., Loffler K., Fechtner M., Arnold W., Giese K., Klippel A., and Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13 (2006) 1222-1234
55. Schiffelers R.M., Koning G.A., Ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., Kok R.J., Molema G., and Storm G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91 (2003) 115-122
56. Schmitt-Sody M., Strieth S., Krasnici S., Sauer B., Schulze B., Teifel M., Michaelis U., Naujoks K., and Dellian M. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 9 (2003) 2335-2341
57. Shimizu K., Asai T., Fuse C., Sadzuka Y., Sonobe T., Ogino K., Taki T., Tanaka T., and Oku N. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int. J. Pharm. 296 (2005) 133-141
58. Shimizu K., Sawazaki Y., Tanaka T., Asai T., and Oku N. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug. Biol. Pharm. Bull. 31 (2008) 95-98
59. Sica A., Saccani A., and Mantovani A. Tumor-associated macrophages: a molecular perspective. Int. Immunopharmacol. 2 (2002) 1045-1054
60. Strieth S., Eichhorn M.E., Sauer B., Schulze B., Teifel M., Michaelis U., and Dellian M. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer 110 (2004) 117-124
61. Strieth S., Nussbaum C.F., Eichhorn M.E., Fuhrmann M., Teifel M., Michaelis U., Berghaus A., and Dellian M. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int. J. Cancer 122 (2008) 452-460
62. Takeuchi Y., Kurohane K., Ichikawa K., Yonezawa S., Nango M., and Oku N. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer 97 (2003) 2027-2034
63. Takeuchi Y., Kurohane K., Nango M., and Oku N. Intensive tumor suppression by anti-angiogenic photodynamic therapy with polycation-modified liposomal photosensitizer. Cell. Mol. Biol. Lett. 7 (2002) 301
64. Temming K., Schiffelers R.M., Molema G., and Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat. 8 (2005) 381-402
65. Thurston G., Mclean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., and Mcdonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101 (1998) 1401-1413
66. Turk M.J., Waters D.J., and Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213 (2004) 165-172
67. Vineis P., and Berwick M. The population dynamics of cancer: a Darwinian perspective. Int. J. Epidemiol. 35 (2006) 1151-1159
68. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre (1863), August Hirschwald Verlag, Berlin
69. Volkel T., Holig P., Merdan T., Muller R., and Kontermann R.E. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta 1663 (2004) 158-166
70. Weiss D.W. Neoplastic disease and tumor immunology from the perspective of host-parasite relationships. Natl. Cancer Inst. Monogr. 44 (1976) 115-122
71. Yonezawa S., Asai T., and Oku N. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. J. Control. Release 118 (2007) 303-309
72. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., and Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 95 (2006) 272-281
73. Zurita A.J., Arap W., and Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J. Control. Release 91 (2003) 183-186